文献速递神经MR

区域与容积参数用于弥散加权WHO II级和III级胶质瘤基因分型的方法比较

Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison.
PubMed 文献 · AJNR Am J Neuroradiol · 2021-01-07

本研究纳入283例初治WHO II级和III级胶质瘤患者(79例IDH野生型、204例IDH突变型),由3名不知组织结果的神经影像医师比较区域ROI与容积VOI的ADC测量方法预测IDH状态的能力。全人群ROI平均归一化ADC与VOI平均归一化ADC的AUC分别为0.83和0.82;在环形强化中央坏死肿瘤(n=23)中仅容积测量有预测价值(AUC=0.90)。结论认为区域归一化平均ADC测量在定义实性胶质瘤IDH状态方面不劣于容积分割,部分坏死环形强化肿瘤不适合ROI评估、可能受益于容积ADC定量。

要点

  • ROI平均归一化ADC与VOI平均归一化ADC预测IDH状态的AUC分别为0.83和0.82。
  • 非强化及实性斑片状强化胶质瘤的ROI基因分型结果与容积参数相当(AUC=0.81-0.84)。
  • 环形强化中央坏死肿瘤(n=23)仅容积测量有预测价值(AUC=0.90),不适合ROI评估。

核心结论

  • 区域归一化平均ADC测量在定义实性胶质瘤IDH状态方面不劣于容积分割。
  • 部分坏死、环形强化的肿瘤不适合ROI评估,可能受益于容积ADC定量。

研究设计与样本

  • 研究纳入283例初治WHO II级和III级胶质瘤患者,其中IDH野生型79例、IDH突变型204例。
  • 由3名不知组织学结果的神经影像医师阅读分析。
  • 在肿瘤及表现正常的白质中定义ADC最小值和平均值ROI以计算归一化值,并将T2加权肿瘤VOI配准至ADC图提取直方图参数(平均值、第2和第5百分位数)。
  • 采用非参数检验(eta2和ANOVA)分析ADC指标与胶质瘤基因型的关联,并用逻辑回归评估VOI和ROI指标预测IDH状态的能力。

诊断标准与关键数值

  • 全人群中,IDH状态预测最准确的是ROI平均归一化ADC和VOI平均归一化ADC,AUC分别为0.83和0.82。
  • 非强化及实性斑片状强化胶质瘤的ROI基因分型结果与容积参数相当,AUC=0.81-0.84。
  • 环形强化中央坏死肿瘤(n=23)中仅容积测量有预测价值,AUC=0.90。

临床应用与阅片要点

  • 实性胶质瘤的IDH状态评估可采用区域归一化平均ADC测量,其表现不劣于容积分割。
  • 对部分坏死、环形强化的肿瘤,ROI评估不适用,作者认为可能受益于容积ADC定量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Studies consistently report lower ADC values in isocitrate dehydrogenase (IDH) wild-type gliomas than in IDH mutant tumors, but their methods and thresholds vary. This research aimed to compare volumetric and regional ADC measurement techniques for glioma genotyping, with a focus on IDH status prediction.

MATERIALS AND METHODS: Treatment-naïve World Health Organization grade II and III gliomas were analyzed by 3 neuroradiologist readers blinded to tissue results. ADC minimum and mean ROIs were defined in tumor and in normal-appearing white matter to calculate normalized values. T2-weighted tumor VOIs were registered to ADC maps with histogram parameters (mean, 2nd and 5th percentiles) extracted. Nonparametric testing (eta2 and ANOVA) was performed to identify associations between ADC metrics and glioma genotypes. Logistic regression was used to probe the ability of VOI and ROI metrics to predict IDH status.

RESULTS: The study included 283 patients with 79 IDH wild-type and 204 IDH mutant gliomas. Across the study population, IDH status was most accurately predicted by ROI mean normalized ADC and VOI mean normalized ADC, with areas under the curve of 0.83 and 0.82, respectively. The results for ROI-based genotyping of nonenhancing and solid-patchy enhancing gliomas were comparable with volumetric parameters (area under the curve = 0.81-0.84). In rim-enhancing, centrally necrotic tumors (n = 23), only volumetric measurements were predictive (0.90).

CONCLUSIONS: Regional normalized mean ADC measurements are noninferior to volumetric segmentation for defining solid glioma IDH status. Partially necrotic, rim-enhancing tumors are unsuitable for ROI assessment and may benefit from volumetric ADC quantification.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Thust SC, Maynard JA, Benenati M, et al. Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison. AJNR Am J Neuroradiol. 2021. PMID: 33414227. doi:10.3174/ajnr.A6965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。